Evidence map›Paper›PMID 26302329›Full record

ArticlePloS one2015

Tumor Suppressor WWOX Contributes to the Elimination of Tumorigenic Cells in Drosophila melanogaster.

Louise V O'Keefe, Cheng Shoou Lee, Amanda Choo, Robert I Richards

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 17 citations in OpenAlex.

  1. Alzheimer's disease risk geneBrain communications · 2026
    Article
  2. WWOX and metabolic regulation in normal and pathological conditions.Journal of molecular medicine (Berlin, Germany) · 2022
    Review
  3. Article
  4. Review
  5. Article
  6. Cancers · 2021
    Article
  7. Fragile GeneFrontiers in oncology · 2021
    Article
  8. Review
  9. WWOX PossessesCancers · 2019
    Article
  10. Article
  11. Article
  12. Article
  13. Modeling WWOX Loss of FunctionFrontiers in oncology · 2018
    Review
  14. Article
  15. HYAL-2-WWOX-SMAD4 Signaling in Cell Death and Anticancer Response.Frontiers in cell and developmental biology · 2016
    Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Louise V O'KeefeDepartment of Genetics and Evolution, Centre for Molecular Pathology, School of Biological Sciences, The University of Adelaide, Adelaide, Australia.
Cheng Shoou LeeDepartment of Genetics and Evolution, Centre for Molecular Pathology, School of Biological Sciences, The University of Adelaide, Adelaide, Australia.
Amanda ChooDepartment of Genetics and Evolution, Centre for Molecular Pathology, School of Biological Sciences, The University of Adelaide, Adelaide, Australia.
Robert I RichardsDepartment of Genetics and Evolution, Centre for Molecular Pathology, School of Biological Sciences, The University of Adelaide, Adelaide, Australia.
University of Adelaide · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

WWOX is a >1 Mb gene spanning FRA16D Common Chromosomal Fragile Site, a region of DNA instability in cancer. Consequently, altered WWOX levels have been observed in a wide variety of cancers. In vitro studies have identified a large number and variety of potential roles for WWOX. Although its normal role in vivo and functional contribution to cancer have not been fully defined, WWOX does have an integral role in metabolism and can suppress tumor growth. Using Drosophila melanogaster as an in vivo model system, we find that WWOX is a modulator of TNFα/Egr-mediated cell death. We found that altered levels of WWOX can modify phenotypes generated by low level ectopic expression of TNFα/Egr and this corresponds to altered levels of Caspase 3 activity. These results demonstrate an in vivo role for WWOX in promoting cell death. This form of cell death is accompanied by an increase in levels of reactive oxygen species, the regulation of which we have previously shown can also be modified by altered WWOX activity. We now hypothesise that, through regulation of reactive oxygen species, WWOX constitutes a link between alterations in cellular metabolism observed in cancer cells and their ability to evade normal cell death pathways. We have further shown that WWOX activity is required for the efficient removal of tumorigenic cells from a developing epithelial tissue. Together these results provide a molecular basis for the tumor suppressor functions of WWOX and the better prognosis observed in cancer patients with higher levels of WWOX activity. Understanding the conserved cellular pathways to which WWOX contributes provides novel possibilities for the development of therapeutic approaches to restore WWOX function in cancer.

Indexed as

AnimalsCaspase 3Cell DeathCell Transformation, NeoplasticChromosome Fragile SitesDisease Models, AnimalDrosophila melanogasterDrosophila ProteinsGene Expression Regulation, NeoplasticHumansNeoplasmsTumor Necrosis Factor-alphaTumor Suppressor ProteinsWW Domain-Containing OxidoreductaseCaspase 3Drosophila ProteinsTumor Necrosis Factor-alphaTumor Suppressor ProteinsWW Domain-Containing OxidoreductaseWWOX protein, Drosophila

Identifiers

PMID26302329
PMCPMC4547717
OpenAlexW1901250449

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.